Your browser doesn't support javascript.
loading
Successful rapid liposomal amphotericin B desensitization in pediatric case series.
Genis, Cankat; Sengul Emeksiz, Zeynep; Buyuk Yaytokgil, Sule; Ginis, Tayfur; Islamoglu, Candan; Dibek Misirlioglu, Emine.
Affiliation
  • Genis C; From the Department of Paediatric Allergy and Immunology, University of Health Sciences, Ankara City Hospital, Ankara, Turkey.
  • Sengul Emeksiz Z; From the Department of Paediatric Allergy and Immunology, University of Health Sciences, Ankara City Hospital, Ankara, Turkey.
  • Buyuk Yaytokgil S; From the Department of Paediatric Allergy and Immunology, University of Health Sciences, Ankara City Hospital, Ankara, Turkey.
  • Ginis T; From the Department of Paediatric Allergy and Immunology, University of Health Sciences, Ankara City Hospital, Ankara, Turkey.
  • Islamoglu C; From the Department of Paediatric Allergy and Immunology, University of Health Sciences, Ankara City Hospital, Ankara, Turkey.
  • Dibek Misirlioglu E; From the Department of Paediatric Allergy and Immunology, University of Health Sciences, Ankara City Hospital, Ankara, Turkey.
Allergy Asthma Proc ; 45(3): 201-206, 2024 05 01.
Article in En | MEDLINE | ID: mdl-38755786
ABSTRACT

Background:

Liposomal amphotericin B (LAMB) is a crucial agent in the treatment of invasive fungal diseases caused by a wide variety of yeasts and molds. In the presence of an infection caused by a fungal agent resistant to alternative antifungal drugs, desensitization may be the only option to continue treatment. However, there is insufficient information and consensus with regard to amphotericin B desensitization protocols in the pediatric age group.

Objective:

We present our experience with five cases of patients in whom successful desensitization protocols were applied with LAMB, along with a review of the literature on pediatric cases. We also provide a sample desensitization protocol that we successfully applied.

Methods:

Pediatric patients who continued their treatment with the successful rapid desensitization protocol conducted at the Paediatric Allergy and Immunology Clinic of the Ministry of Health Ankara City Hospital between September 2019 and September 2023 were examined. Desensitization protocols were applied based on Castells' desensitization protocol.

Results:

Five patients ages between 5 and 12 years were referred to us due to the development of anaphylaxis during their treatment with LAMB. Anaphylaxis is diagnosed clinically, according to the European Academy of Allergy and Clinical Immunology guidelines anaphylaxis (2021 update). A 16-step desensitization protocol was prepared by using LAMB solutions at four different dilutions (0.001, 0.01, 0.1, and 1 mg/mL). Each solution consisted of four steps, with a 15-minute infusion for each step. The patients were premedicated with 1 mg/kg/dose methylprednisolone and an antihistamine.

Conclusion:

The data we present on the successful application of a sample protocol to five cases, particularly in a pediatric setting, are noteworthy valuable contributions to the field, which demonstrates the feasibility and success of rapid desensitization with LAMB in pediatric patients. This can provide important insights and potentially serve as a reference for medical professionals working with similar cases in the future.
Subject(s)

Full text: 1 Database: MEDLINE Main subject: Amphotericin B / Desensitization, Immunologic / Drug Hypersensitivity / Antifungal Agents Limits: Child / Child, preschool / Humans Language: En Year: 2024 Type: Article

Full text: 1 Database: MEDLINE Main subject: Amphotericin B / Desensitization, Immunologic / Drug Hypersensitivity / Antifungal Agents Limits: Child / Child, preschool / Humans Language: En Year: 2024 Type: Article